Welcome to our dedicated page for Phreesia SEC filings (Ticker: PHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Phreesia filings document the company’s operating results, material agreements, capital structure and governance as a public healthcare technology company. Recent Form 8-K disclosures include quarterly financial results, stakeholder letters and earnings-call materials, along with material definitive agreements connected to credit facilities, acquisition financing and receivables arrangements.
The filing record also documents the completed AccessOne acquisition, the use and refinancing of related debt, and subsidiary arrangements involving AccessOne Funding and AccessOne MedCard. Governance disclosures include board composition changes, director compensation matters and shareholder-voting subjects, while capital-structure disclosures cover secured revolving credit, bridge-loan obligations and receivables purchase agreements.
Phreesia (PHR) reported an insider equity award by Director Gillian Munson. On 10/31/2025, the director acquired 441 shares reported as common stock at $22.64, reflecting deferred stock units (DSUs) elected in lieu of an annual cash retainer. Following the transaction, the director beneficially owned 44,985 shares, held directly.
Per the program terms, the DSUs convert into underlying common stock on the earlier of 90 days after the director’s separation from the Board (as defined under Section 409A) or five years from the grant date.
Phreesia (PHR) director reported acquiring 441 shares of common stock at $22.64 on 10/31/2025, recorded via deferred stock units under the company’s Non‑Employee Director Deferred Compensation Program. Following this transaction, the director beneficially owns 63,784 shares directly.
The DSUs were granted in lieu of a cash retainer paid quarterly in arrears. Underlying common shares are deliverable on the earlier of 90 days after the director ceases Board service and incurs a separation from service or five years from the grant date.
The Vanguard Group filed Amendment No. 3 to Schedule 13G reporting beneficial ownership of 5,704,786 shares of Phreesia (PHR) common stock, representing 9.52% of the class as of 09/30/2025.
The filing lists 0 shares with sole voting power and 386,223 with shared voting power. It reports 5,246,543 shares with sole dispositive power and 458,243 with shared dispositive power. Vanguard certifies the securities were acquired and are held in the ordinary course of business and not to influence control of the issuer.
Vanguard identifies its reporting person type as IA (investment adviser), noting its clients have rights to dividends or sale proceeds; no single client’s interest exceeds five percent.
Phreesia (PHR) disclosed a Form 4 for CFO Balaji Gandhi. On 10/17/2025, he disposed of 885 shares of common stock at a weighted average price of $22.3612 in non‑discretionary sell‑to‑cover transactions to satisfy tax withholding tied to the settlement of restricted stock units.
Following the sale, he beneficially owns 98,240 shares, held directly. The shares were sold across multiple trades at prices ranging from $22.195 to $22.66 per share.
Phreesia, Inc. (PHR) reported an insider transaction by its General Counsel & Secretary. On 10/17/2025, the officer sold 1,241 shares of common stock (code S) in non-discretionary transactions executed under the company’s mandatory sell-to-cover policy tied to RSU settlement.
The weighted average sale price was $22.3612 per share, with individual trades ranging from $22.195 to $22.66. Following these transactions, the officer directly beneficially owned 135,737 shares.
Phreesia (PHR) insider activity: CEO and director Chaim Indig reported a sale of 3,163 shares of common stock on 10/17/2025. The filing states these shares were disposed of in non-discretionary transactions under the company’s mandatory sell-to-cover policy to satisfy tax withholding tied to the settlement of restricted stock units.
The weighted average sale price was $22.3612 per share, with individual trades executed between $22.195 and $22.66. Following the transaction, Indig beneficially owned 1,252,608 shares directly. An additional 255,000 shares were listed as indirectly owned through a family trust, whose sole beneficiaries are members of his immediate family.
Phreesia (PHR) reported an insider transaction by its President, Network Solutions. On 10/17/2025, the reporting person sold 2,059 shares of common stock (code S) at a weighted average price of $22.3612. The filing states the sales were non‑discretionary under the company’s mandatory sell‑to‑cover policy to satisfy tax withholding tied to the settlement of restricted stock units.
Following the transaction, the insider beneficially owned 171,829 shares directly and 9,883 shares indirectly through a spouse.
Phreesia (PHR): Officer Evan Roberts reported a Form 4 transaction showing the sale of 1,888 shares of common stock on 10/17/2025 at a weighted average price of $22.3612. The filing states the shares were disposed of in non-discretionary transactions under the issuer’s mandatory sell-to-cover policy to satisfy tax withholding tied to the settlement of performance-based RSUs.
Following the transaction, Roberts beneficially owned 724,949 shares, held directly.
Phreesia, Inc. (PHR) reported a Form 4 showing an officer transaction tied to tax withholding. On 10/17/2025, the company’s SVP, Human Resources disposed of 639 shares of common stock in non-discretionary sales under the issuer’s mandatory sell-to-cover policy related to the settlement of restricted stock units. The weighted average price was $22.3612, with individual trades executed between $22.195 and $22.66 per share.
Following the transactions, the reporting person beneficially owned 111,840 shares, held directly. The filing notes the availability of detailed trade breakdowns upon request.
Phreesia (PHR): A selling securityholder filed a Form 144 to sell 885 shares of common stock, with an approximate sale date of 10/17/2025 on the NYSE and an aggregate market value of 19789.66.
The 885 shares were acquired via restricted stock vesting on 10/14/2025 as compensation from the issuer. Shares outstanding were 59914473.
Recent Form 144 activity by Balaji Gandhi shows sales of 886 shares on 07/17/2025 for 23820.82, 9583 shares on 08/25/2025 for 287550.07, and 4183 shares on 09/16/2025 for 97398.65.